Literature DB >> 8132836

Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma.

M H Cummings1, G F Watts, P J Lumb, B M Slavin.   

Abstract

To assess whether the Lowry-tetramethylurea method for measuring apolipoprotein B-100 (apo-B) in very low density lipoprotein (VLDL) could be replaced by direct assay of VLDL apo-B using a highly practicable immunological method. Seventy five fasting blood samples were collected from patients attending the lipid clinic at this hospital. Plasma was separated immediately and VLDL isolated by preparative ultracentrifugation at solution density 0.93-1.006 kg/l. Apo-B was precipitated from an aliquot of the VLDL fraction using the tetramethylurea (TMU) technique and protein mass determined by the Lowry method (LM); mean apo-B 83.02 micrograms/ml (SD 74.85). Apo-B was also measured in VLDL using direct immunoturbidimetry on the Cobas-Fara analyser; mean apo-B 82.32 micrograms/ml (SD 72.88). There was a very close correlation between methods (immunoturbidimetry = 0.94.LM + 3.95, r = 0.97, p < 0.001). The mean difference between methods (constant error) was small (0.70 microgram/ml) and not significant (p = 0.742). Random error was 13.01 micrograms/ml by analysis of variance. It is concluded that immunoturbidimetry, a more rapid and convenient test, may replace the LM and TMU techniques for measuring VLDL apo-B concentration and that this method could be applied to research studies requiring analysis of large numbers of samples.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132836      PMCID: PMC501839          DOI: 10.1136/jcp.47.2.176

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Electroimmunoassay of a subunit protein in a macromolecular complex (apolipoprotein B in human plasma very low density lipoprotein); implications for other electroimmunoassay systems.

Authors:  G D Calvert; R A Yeates; D C Roeger
Journal:  Clin Chim Acta       Date:  1979-10-01       Impact factor: 3.786

Review 2.  Immunological assays of apolipoproteins in plasma: methods and instrumentation.

Authors:  C Labeur; J Shepherd; M Rosseneu
Journal:  Clin Chem       Date:  1990-04       Impact factor: 8.327

3.  Immunoturbidimetric assays for serum apolipoproteins A1 and B using Cobas Bio centrifugal analyser.

Authors:  J N Mount; E M Kearney; M Rosseneu; B M Slavin
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

Review 4.  Cardiovascular molecular biology. Introduction to the series.

Authors:  K R Chien; K U Knowlton
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

5.  Apoprotein composition of very low density lipoproteins of human serum.

Authors:  J P Kane; T Sata; R L Hamilton; R J Havel
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

6.  Enzyme-linked immunosorbent assay for human plasma apolipoprotein B.

Authors:  J M Ordovas; J P Peterson; P Santaniello; J S Cohn; P W Wilson; E J Schaefer
Journal:  J Lipid Res       Date:  1987-10       Impact factor: 5.922

Review 7.  Clinical value of apolipoprotein measurement.

Authors:  D Bhatnagar; P N Durrington
Journal:  Ann Clin Biochem       Date:  1991-09       Impact factor: 2.057

8.  Immunoturbidimetric method for routine determinations of apolipoproteins A-I and B.

Authors:  D Brustolin; M Maierna; F Aguzzi; F Zoppi; G Tarenghi; G Berti
Journal:  Clin Chem       Date:  1991-05       Impact factor: 8.327

  8 in total
  2 in total

1.  Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease).

Authors:  A S Wierzbicki; G F Watt; J Lynas; A F Winder; R Wray
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

2.  Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.

Authors:  M H Cummings; G F Watts; A M Umpleby; T R Hennessy; R Naoumova; B M Slavin; G R Thompson; P H Sönksen
Journal:  Diabetologia       Date:  1995-08       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.